The Joint (US:JYNT) Prnewswire·2025-02-11 14:15Core Viewpoint - Oramed Pharmaceuticals Inc. has announced the spin-off of its Protein Oral Delivery (POD™) technology into a new joint venture, OraTech Pharmaceuticals Inc., aimed at accelerating the development and commercialization of oral insulin and other innovative oral drug delivery technologies [1][2][4]. Group 1: Company Structure and Financials - Oramed will transfer its proprietary oral insulin and POD™ technology, along with other pipeline assets, into OraTech, allowing Oramed shareholders to receive a majority equity interest in the new entity [2][7]. - Oramed and Hefei Tianhui Biotech Co., Ltd. (HTIT) will contribute a combined $75 million in capital to OraTech, with HTIT investing $60 million and Oramed investing $15 million [2][7]. - OraTech will have global marketing rights to Oramed's POD™ oral protein delivery technology [7]. Group 2: Strategic Focus and Development Plans - OraTech will focus on bringing oral insulin to market and exploring broader applications of oral drug delivery for additional therapeutic targets [3][4]. - A pivotal Phase 3 clinical trial in the United States is planned to be reinitiated, with a revised protocol expected to begin this quarter [7]. - OraTech aims to advance the registration of oral insulin in the U.S. and other countries, and will receive royalty payments from sales of oral insulin in China, where a Marketing Authorization Application has been submitted [7]. Group 3: Manufacturing and Operational Capabilities - OraTech will leverage HTIT's advanced manufacturing capabilities, particularly in capsule production, to ensure a robust and scalable supply chain for clinical trials and commercialization efforts [3][4]. - The collaboration is expected to enhance the development and commercialization of Oramed's ORMD-0801 oral insulin and other POD™-based technologies, reinforcing the vision of revolutionizing diabetes and chronic disease treatments [1][8].